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The Rutgers conference of the National Agricultural Biotechnology Council
represents a potential turning point in public debates over the future of plant
and animal applications of recombinant DNA manipulation and other
techniques of biotechnology. Prior to the conference, debate over food and
agricultural biotechnology was focused on three product groups: herbicide
tolerant crops, animal drugs (especially BST), and crops engineered with the Bt
gene. Although there are a few important exceptions, most products approved
for use in the United States fall into one of those three groups. Debate over
those products created an alignment of interests where agricultural input
suppliers, the food industry, and commodity organizations opposed a coalition
of interest groups representing food consumers, environmental and animal
protectionists, and small scale farmers. Universities and government were
caught in the middle. Only a few products (notably recombinant chymosin,
the enzyme used in the production of cheese) escaped.
The Rutgers meeting provided an overview of the products that may come
on-line from agricultural biotechnology early in the next century. The papers
in this conference report describe new food products that will do far more
to enhance the dimensions of quality that are important to consumers: taste,
purity, and visual appeal. If the food industry can ensure the safety of bio-
technology foods (arguably in place now at the Food and Drug Administration
(FDA)) and protect the principle of individual consent and control (labels are
arguably the answer), these new products will enjoy consumer support, rather
than opposition. What is more, new food crops that emphasize disease
resistance or that utilize less toxic forms of pest control (such as Bt crops)
should garner support from the environmental community.
Authors for this NABC 8 report also note the potential for using crops and
animals in the production of pharmaceutical and industrial products. If past
history is any guide, the public will find the case for new or less expensive
forms of human medicine a compelling one. New industrial products are among
the most exciting possibilities, as applications of both plant and microbial bio-
technology permit the production of fiber and cellulose crops that can relieve
pressure on the worlds forests. The potential for liquid fuels holds out the
promise of transferring a significant part of global energy consumption from a
non-renewable to a renewable basis. Granted, the potential for such products
must not be allowed to substitute for the strides that society has made in
conservation, but there is every reason to hope that they may become a new
approach as we strive for a sustainable society.
What constraints pose challenges to the emergence of these new uses for plant and
animal biotechnology, and what new opportunities do these novel products portend?
The papers in this report provide some insight into this two pronged question.
One way of tying them all together is to recognize a synergy in both the chal-
lenges and the opportunities. A negative synergy of constraints places serious
roadblocks in the path of developing these novel products, but with a few key
changes that synergy could become strongly positive. Those key changes
revolve around two points: trust and vision.
CHALLENGES
The novel products discussed in the chapters of this report range from new
foods that are entering the regulatory process (needing “only” regulatory
approval and commercialization before becoming available on grocery shelves)
to liquid fuels derived from plant biomass (that are, at present, largely a gleam
in the eye of bench scientists conducting basic research). Yet, in every case, new
technology will be needed to make the product a reality. In the former cases, it
is scale-up technology needed for commercial production, or “soft” technology
in the form of better marketing and consumer information. In the latter cases,
basic problems in biochemistry, molecular biology, and process engineering are
yet to be solved. The current state of knowledge is therefore a constraint that
must be removed before the novel products described herein can become
widely available.
Removing knowledge-based constraints will require research in biology,
engineering, and social science. Research will require both human and financial
capital. Although a lack of either could retard development of novel products,
it seems reasonable to think that lack of money is a more serious constraint at
the present time. Public sector funding for all forms of scientific research has
been declining, and venture or investment capital for speculative biotechnology
projects outside the area of human health has become scarce. The major
agricultural biotechnology companies have herbicide tolerant or Bt crops
and animal drugs to develop. It is questionable whether they will have the
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additional resources, or be willing to invest in the research needed, to bring
novel products to market.
One reason why investors may be reluctant to fund research in these novel
products is that commercialization will require infrastructure and institutions
that do not exist. Think for a moment about what will be required to get
industrial fiber grown in Iowa or Illinois to the pulp mills that are now located
near the pine forests of Alabama or South Carolina. Note that there are no
commodity organizations for growers of hemp, or for producers of pharma-
ceuticals utilizing plants or farm animals. Do petroleum buyers or oil company
executives traverse the Dakotas in search of new sources of supply? Novel
products presuppose new and untried linkages between farm-based suppliers
and the eventual buyers and users of their products; these linkages will have
to be invented. It is reasonable to think that in the case of pharmaceutical
products, vertically integrated firms will round-up the growers or husbandry-
men they need, but even so, these contracting activities represent costs that
must be included in the commercialization of such novel products.
The regulatory framework is also a crucial dimension of infrastructure for
novel products. The FDA evaluates food safety, as well as the safety and effec-
tiveness of new drugs. The direct environmental risks of new crops are also
reviewed by the Environmental Protection Agency (EPA) and the Animal
and Plant Health Inspection Service (APHIS) at the USDA. This much of the
regulatory framework is in place. But do pharmaceutical or industrial crops
and animals pose new risks to the food system? Is there any chance that milk
from cows genetically engineered to lactate pharmaceutical products could
contaminate the milk supply? Could crops engineered for fiber or ethanol
production back cross into varieties produced for food, and if so, what are the
risks? These do not seem to be insurmountable problems, yet they will require
forms of regulatory oversight that do not currently exist.
Developing institutions and infrastructure will be very difficult if there is
public opposition to the products themselves. Vertical organization of produc-
tion may be the most cost effective method for coordinating suppliers or for
maintaining the quality control needed for new food, pharmaceutical, and
industrial products, but such changes in the structural organization of agri-
culture may be opposed by consumers and farm groups alike. Because it is
unclear whether people will oppose the integration and industrialization of
agriculture, the uncertainty itself comes to constrain efforts to build infra-
structure or to design institutions, as well as being a disincentive for investing
the money needed to support additional research. If there is a residue of public
resistance to agricultural biotechnology—as a result of acrimony over BST or
as a reaction against “playing God,” perhaps—the uncertainties are heightened,
and the risks of undertaking the research and development of these novel
(hence speculative) products begins to seem formidable indeed.
There is thus a synergy that binds the knowledge constraints, the funding
constraints, the infrastructure constraints, and the public acceptance con-
straints. Each constraint tends to reinforce the other three. How could the
public be anything but skeptical of products descended from the heritage
of controversy over herbicide tolerant crops and BST, especially when even
their boosters acknowledge that too little is known at present to make those
products a reality, and when even venture capitalists are reluctant to invest
in them? Yet public skepticism retards the development of infrastructure
(including regulatory frameworks) and undermines the support for funding
that would ultimately address public concerns. One might conclude that the
likelihood of seeing any of those novel products in our lifetimes is slim.
OPPORTUNITIES
But, on the other hand, those products are more attractive to consumers, to
environmental interests, and, if fears of vertical integration can be assuaged,
perhaps even to small-scale producers. It is certainly the case that high quality
fruit and vegetable production is already a mainstay of family farmers in the
Northeast. New pharmaceutical products may well be produced on scales quite
commensurate with small farms, and if drug companies do not insist on con-
trolling the entire process, those products, too, may provide opportunities for
small-scale producers to maintain a way of life. As such, it need not be a fore-
gone conclusion that the public will oppose these products. A new coalition
of interest groups might provide impressive support for them.
If a new coalition forms, it will have the capacity to address problems of
infrastructure and funding in novel ways. Perhaps it will be possible for
environmentalists to work with producers and industry to restructure the
regulatory process for novel products. Perhaps regulatory functions can even
be incorporated into organizations that reflect multiple constituencies, on the
model of the Underwriters Laboratory. Small- and large-scale producers may
wish to form new kinds of cooperative organizations to ensure that they main-
tain control over the market structure for those new products, and they may
find themselves in partnership with industry giants as well as public interest
groups that have a stake in seeing those technologies develop. Clearly such
coalitions will have advantages in attracting investment funding, if only because
they reduce uncertainty. The possibility of co-ops, working with consumer and
public interest groups, in partnerships with industry for development of novel
products produces a mind-bending alteration of what we might mean by
“community supported agriculture” in the 21st century.
The potential for such new social amalgamations is no less innovative and
radical than the biological amalgamations discussed throughout this volume.
Tomorrow might look very different, and not only because we will have
genetically engineered foods, fuels, and pharmaceuticals! This, of course,
implies greater involvement of more people in setting the agenda for research
on agricultural biotechnology, and it probably means that more kinds of
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research will need to be done. The fact that such research will be popular
bodes well for getting it supported not only by government but by private
foundations, too. There is potential for a positive synergy, for research progress
to beget public enthusiasm and cooperation, and for this enthusiasm to beget
new institutions and new approaches to infrastructure. And these new insti-
tutions may provide both new sources of capital and renewed vigor in the old
sources of government, foundation, and Wall Street fundraising.
This is an admittedly sketchy picture of the new positive synergy. A lot of
problems will need to be solved along the way, and many of the real concerns
about the novel products themselves, as well as residual problems from existing
products of agricultural biotechnology, still need to be addressed. Nevertheless,
there is reason to think that new coalitions will have enthusiasm for such tasks
to the extent that they see themselves engaged in activities that are truly aimed
at improving the human condition, including, of course, the environment on
which that condition depends. Will it happen? Who knows, but at least two
“big picture” items are key. One is trust, the other is vision.
KEYS TO POSITIVE SYNERGY: TRUST
A world in which the food industry, small and large food and fiber producers,
and public interest organizations representing environmental, animal, and
consumer interests work with each other (as well as with other industries) will
require new levels of trust. It would be naive to suggest that such collaborations
will come easily, and it is important to think carefully about what is meant by
trust. Philosopher Annette Baier offers some guideposts in her recent book
Moral Prejudices: Essays on Ethics. Writing from a feminist perspective, she
encourages us to resist an interpretation of trust that confuses trust with power.
It is an unavoidable fact of human society that some of us depend upon others
for our jobs, our food, our health care, and for other aspects of our well-being.
These relationships define relative positions of power and dependence. In
democratic societies, we often speak of the rules for constraining or using
power in terms of a social contract. Contractually specified power relations
are “minimal moral traffic rules, designed to restrict close encounters between
autonomous persons to self-chosen ones” (Baier 1994). Baier believes that
while the social contract is indispensable to democracy, it is a poor model for
trust. A better model emerges out of women’s experiences raising children,
caring for families, and maintaining networks of care in the community.
Trust applies in situations where explicitly specified rules and contractual
requirements are inadequate or inappropriate. To trust another person is to
expect that there will be situations in which the trustee must exercise judgment
and discernment of a sort that cannot be anticipated and spelled out in terms
ofcontractual provisions. Trust requires that trustees make such decisions based
upon a genuine and comprehensive concern for the interests, the well-being,
and the whole person of those who have placed their trust in them. Yet it is also
true that relationships of trust are bounded, that they come with limits and
with opportunities to monitor, revise, or revoke the trusting relationship. To
put this as Baier does, children do not trust their parents; their dependency
upon them is too great. Parents do trust their children to teachers, to baby-
sitters, or to friends, however, and in doing so they expect something more
subtle and responsive than letter-perfect adherence to the terms of an explicit
contract. They expect situations that have not been anticipated by the contract,
and that the trusted party will maintain trust by acting on behalf of the child,
rather than interpreting the ambiguity or unexpectedness of the situation as
an opportunity to revert to self-interest.
This means that some of the things Rebecca Goldberg and Caron Chess
discuss—regulations that utilize conditional approval or site licenses that give
citizens the power to revoke approval—may not be forms of trust in Baier’s
sense. Those measures seem to be negotiations of power, and our experience
with such negotiations tells us that where there is ambiguity in the terms of
the rule or the contract, we can expect each party to adopt the interpretation
that is most favorable to themselves. Make no mistake, I am not arguing against
institutions that spread power and that frame power relationships within ex-
plicit statements of rules and responsibilities. But let us not deceive ourselves
into thinking that these are relationships of trust. As Baier writes, “Trust is
rational in the absence of any reason to suspect in the trusted strong and
operative motives which conflict with the demands of trustworthiness as the
truster sees them. But trusting can continue to be rational, even when there
are such unwelcome suspicions, as long as the truster is confident that in the
conflict within the trusted the subversive motives will lose to the conformist
motives” (Baier, 1994).
I take this to mean that each of the parties who must collaborate in order to
create positive synergism for new products in biotechnology must share and
remain true to a common vision, even when there are substantial individual
incentives to defect from it. Perhaps an example will make this point more
clearly. Many members of the National Agricultural Biotechnology Council
have built a trust relationship with farmers, ranchers, and rural communities.
Farmers, ranchers, and rural communities represent diverse interests, and there
has always been difficulty when the knowledge produced in agricultural uni-
versities has benefited some representatives of agriculture at the expense of
others. Agricultural research is also justified in terms of benefit to the larger
non-agricultural public, but the trust relationship between agriculture colleges
and their clientele continues to imply that the scientists, administrators, and
faculty of agriculture colleges and research stations are making judgments
on behalf of agriculture. Yet, though there can be little doubt that many of
the novel products described in these pages are intended for public benefit,
it is questionable for some (at least) as to whether they are truly agricultural
biotechnology.
Novel products are exciting applications of the plant and animal sciences to
the creation of products for human medicine or industrial processes, and they
are in this sense good for the scientists, administrators, and faculty of agricul-
tural colleges. But it is not obvious that such products will ever be produced by
people who today recognize themselves as farmers or ranchers, or on the terms
that characterize the traditional economic structure of agriculturally based
communities. Are we being entirely honest, are we maintaining our trust, when
we describe these as novel products of agricultural biotechnology? Will small-
scale niche producers ever produce pigs for pharmaceutical production or
xenografts, or will those pigs be cared for in facilities that are wholly owned
and operated by medical supply or drug companies? Is it fair to say that we are
helping agriculture, when in fact the most we are doing is creating wage labor
opportunities to care for pigs in the employ of large multi-national corporations?
None of this is to say that such innovations should not be pursued, nor is it
to say that scientists currently employed in agricultural universities should not
do the work. Yet here, I think, is a way in which members of the research world
can defect from the common vision of agriculture that underlies rural com-
munity support for research and education. Researchers may not mean to betray
a trust. They may think, with some justification, that they are acting within
their rights, but that is only to underscore Baier’s point. Relationships of trust
are not simply a matter of following the rules and obeying the law. Trust re-
quires judicious thought about whether what is done is truly done for the sake
of those who trust, or whether personal motives and opportunities may have
colored the common vision. Since the point has now come to turn to vision,
let us take up the second key.
KEYS TO SYNERGY: VISION
Many of the institutional members of the National Agricultural Biotechnology
Council have been engaged in processes of “visioning” during 1995 and 1996,
so much so that the term may have lost whatever appeal it once had. Perhaps
we would be better off to use Sister Miriam MacGillis’ term, “cosmology.”
Whatever the terminology, the idea is to recognize that we tell one another
stories about where we have come from and where we are going. Although
these stories (visions) are seldom made explicit, they serve as underlying
assumptions about what is real and what is worth doing. One of those stories
that was told for centuries goes by the name of The Enlightenment Project.
This intimidating phrase signifies the vision of science and technology relieving
the many dimensions of human misery: hunger, disease, and deprivation. The
individuals who conceived this vision, Francis Bacon, Thomas Hobbes, Robert
Boyle, and Rene Descartes among them, lived during the sixteenth century,
almost five hundred years ago. Although in some respects their vision has come
true, they also thought that unleashing the forces of scientific inquiry would
just automatically, naturally redress the social problems of injustice, of cruelty,
of jealousies, and of corruption.
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No one believes that science will automatically redress those moral problems
anymore. What is more, we have learned that our technological solutions to
problems of resource scarcity can create new problems of their own, problems
in the form of pollution, health risk, and environmental degradation. There is
no doubt that we must move beyond The Enlightenment Project, that we must
find a vision (a cosmology if you will) that does not leave the resolution of
moral problems facing us to a blind and inexorable notion of technical progress.
However it has succeeded in other dimensions, that vision of progress has failed
to create a state of bliss at the end of history. We have many problems that have
always been with us, and more than a few new ones, to boot.
The mechanistic vision of nature and humanity that emerged from The
Enlightenment Project has proved an inadequate basis for understanding social
problems, environmental impacts, and the moral significance of technology’s
unexpected and unwanted effects. That much is clear. The Enlightenment
Project may also have encouraged habits of mind that fixated on patterns of
domination: domination of women, domination by race, domination of nature.
The Enlightenment Project may have made us less sensitive to the potential
for adapting to and living with our limitations, rather than trying to overcome
them. It does not follow, however, that we would have been better off never to
have undertaken The Enlightenment Project, nor does it follow from any of
this that we should abandon all use of biotechnology. There is a huge inferential
leap being made by biotechnology’s critics in this regard. We should indeed
devote serious and critical attention to the implicit vision that we may be
working with. Formulating this vision is more important than any specific
application of biotechnology, but only petty jealousy would permit us to blame
biotechnology for our collective failure to address the fundamental spiritual
issues of our time. The practitioners of biotechnology have been spectacularly
successful in acquiring the rewards of new buildings, financial success, and
public attention. It is easy (perhaps inevitable) that those who call for moral
reflection over our pursuit of technological advance should feel neglected and
cast aside. It is only too human to wish ill upon an industry that sometimes
seems willing to exploit the state of disarray and dissolution in our collective
moral vision by making fantastic promises, but the simple fact is that we will
need biotechnology in any adequate response to the ecological and moral crises
of our time.
Our new vision will almost certainly be meliorist. This forty dollar bit of
philosophical jargon means that we will abandon the view that any scientific,
technological, or political project will just automatically solve all our problems.
We will abandon the view that progress is either inevitable or automatic. This
means that we abandon both The Enlightenment Project of dominating nature’s
mechanisms and the conceit that there ever was a truly harmonious nature
(disrupted by human activity) to which we must return. In place of this, we
will recognize the ecologists dictum: everything is connected to everything else.
When we “solve” one problem, we must be prepared to find and fix whatever
breaks next. Life is indeed an evolutionary process, but not one that is tending
toward a state of perfection or bliss. Instead, each adjustment (whether human
caused or not) adumbrates through the global ecosystem, producing myriad
changes, and opening niches for novel life activities (both human and not).
The evolutionary process goes on and on. It is never finished.
The vision for human action is one of ameliorating intolerable situations, one
after another, and using whatever tools are at our disposal to do so. Plant and
animal biotechnology will be among them. Our use of those tools should be
evolutionary, rather than revolutionary. We should use biotechnology as wisely
as we possibly can, and we should be vigilant in monitoring and learning from
our mistakes. We can be sure that there will be some unintended consequences
from using biotechnology, but there will be unintended consequences from not
using biotechnology, too. We should not expect magic bullets from biotech-
nology or from not using it. We should do what we can humbly and reflectively.
That is what meliorism means.
Yet, I would like to say a few words on behalf of Francis Bacon, Thomas
Hobbes, and the other gentlemen of the Enlightenment. Their mechanistic
vision of nature indeed lead to the revolutions in health care, agriculture, and
engineering that brought about the modern world. Would that we could formu-
late a vision half so productive! And while we cannot believe that exclusive
attention to mechanisms will solve our moral and environmental problems,
we should be reminded that thinkers like Bacon and Hobbes fully expected to
spend two hours engaged in debates over philosophy and theology for every
hour spent at the laboratory bench. Who knows what vision and what synergy
we would discover if we were to collectively spend a similar proportion of our
research effort on philosophy, history, and literature.
Reproducing a vision is even more important than the initial discovery of
vision. The time that Enlightenment thinkers spent in debate over moral sub-
jects not only honed their vision of nature and human possibility, it spread that
vision to the clientele who would utilize scientific knowledge. The challenge of
disseminating a vision is altogether different today. For one thing, we have tools
of mass media at our disposal that were unavailable to Bacon and Hobbes, and
we have the advantage of a generally literate society. But we also have a much
larger client base; one that spans a much larger proportion of the population.
It is far from clear whether we can afford to invest less in forming, articulating,
defending, and disseminating a vision than could the founders of the Enlighten-
ment, though it is evident that invest less we do.
The National Agricultural Biotechnology Council and its national confer-
ences are for that reason all the more precious. They represent one of the few
forums in which reflection over science and its impact on our future can take
place. The novel products discussed in this meeting provoke a new reflection
on what that future might entail. It is, for me, a more hopeful future than we
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have hitherto seen. It will not come about without more work in both the
laboratory and in reasoned public debates. To that end, let us dedicate our
hearts and minds.
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